Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-158

Everyone is entitled to their opinion on this forum. However, you just cannot make things up and post clearly misleading and untrue statements such as what you’ve just done:

’It was a shame they didn’t continue the trial at the lower doses that had proved well tolerated and efficacious’ ~ @bid

There were plenty of adverse events related to treatment early in the trials at lower doses and throughout the trials at higher doses evidenced as far back as 2022 from the first AstraZeneca poster presentation.

AstraZeneca reported on multiple occasions that none of the patients had met the formal criteria of a response.

You appear to be just making things up. Do better.